Добірка наукової літератури з теми "De beneficii"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "De beneficii".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "De beneficii"
Dadu, Constantin, Victor Donea, Elisaveta Onica, Ecaterina Donea, and Ion Oboroc. "Alunul obișnuit (Corylus avellana L.) – particularități și beneficii." Pomicultura, Viticultura şi Vinificaţia, no. 1(87) (December 2022): 54–63. http://dx.doi.org/10.53082/1857-3142.22.87.07.
Повний текст джерелаBoia, Mariana, Delia Maria Nicoară, and Aniko Maria Manea. "Riscuri şi beneficii ale terapiei cu metilxantine – studiu de caz." Romanian Journal of Pediatrics 63, no. 3 (September 30, 2014): 309–11. http://dx.doi.org/10.37897/rjp.2014.3.17.
Повний текст джерелаGoicovici, Juanita. "Matricea răspunderii civile extracontractuale pentru prejudiciile cauzate de produsele cu defecte de manufacturare, între testul riscuri-beneficii și testul așteptărilor legitime ale consumatorului." Studia Universitatis Babeş-Bolyai Iurisprudentia 67, no. 1 (July 25, 2022): 106–85. http://dx.doi.org/10.24193/subbiur.67(2022).1.2.
Повний текст джерелаGoicovici, Juanita. "Matricea răspunderii civile extracontractuale pentru prejudiciile cauzate de produsele cu defecte de manufacturare, între testul riscuri-beneficii și testul așteptărilor legitime ale consumatorului." Studia Universitatis Babeş-Bolyai Iurisprudentia 67, no. 1 (July 25, 2022): 106–85. http://dx.doi.org/10.24193/10.24193/subbiur.67(2022).1.2.
Повний текст джерелаBARBU, Dragoș-Cătălin, Gabriela DOBRIȚA (ENE), Simona-Vasilica OPREA, Adela BÂRA, and Vlad DIACONIȚA. "Provocări și beneficii ale sistemului de vot electronic bazat pe Blockchain." Revista Română de Informatică și Automatică 32, no. 4 (December 20, 2022): 117–28. http://dx.doi.org/10.33436/v32i4y202210.
Повний текст джерелаAniței, Mihai, Oana Pănescu, and Mihaela Chraif. "ASPECTE PRACTICE ALE UTILIZĂRII TERAPIEI COGNITIVE ÎN MANAGEMENTUL RESURSELOR UMANE DIN ORGANIZAȚIILE BANCARE." Psihologia Resurselor Umane 5, no. 1 (January 29, 2020): 68–78. http://dx.doi.org/10.24837/pru.v5i1.312.
Повний текст джерелаTapie, Matthew Anthony. "”Out of Zion the Deliverer Shall Come” St. Thomas Aquinas on Jewish Worship as Figura praesentis spiritualis beneficii." European Journal for the Study of Thomas Aquinas 33, no. 1 (December 1, 2013): 76–109. http://dx.doi.org/10.2478/ejsta-2013-0003.
Повний текст джерелаPop, Anghel Marian. "Observații asupra puterii discreţionare a administraţiei prin prisma principiului proporționalității." Studia Universitatis Babeş-Bolyai Iurisprudentia 67, no. 2 (November 30, 2022): 9–43. http://dx.doi.org/10.24193/subbiur.67(2022).2.1.
Повний текст джерелаÖner, Hatice, Belgin Yildirim, and Didem Evci Kiraz. "THE OPINIONS OF NURSING STUDENTS ON ACADEMIC CONSULTANCY SERVICES OPINIA STUDENȚILOR DE LA ASISTENȚĂ MEDICALĂ GENERALĂ CU PRIVIRE LA SERVICIILE DE CONSULTANȚĂ ACADEMICĂ." Jurnal Medical Brasovean, no. 1 (August 10, 2020): 97–111. http://dx.doi.org/10.31926/jmb.2020.1.15.
Повний текст джерелаBĂIȚAN, George-Florin. "LUPTA CORP LA CORP CU SAU FĂRĂ ARMAMENTUL PORTABIL DIN DOTARE – ELEMENTE FUNDAMENTALE PENTRU INSTRUIREA MILITARULUI MODERN." Buletinul Universității Naționale de Apărare „Carol I” 9, no. 2 (July 2, 2021): 130–39. http://dx.doi.org/10.53477/2065-8281-21-16.
Повний текст джерелаДисертації з теми "De beneficii"
Vilamala, Salvans Jordi. "Una Seu, dos col·legis: la comunitat de beneficiats de l’església de la Pietat de Vic. Les repercussions socials del nou ordre tridentí (1613-1664)." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/666897.
Повний текст джерелаThis thesis analyses how the dispositions that resulted from the Trento Council (1545-1563) evolved the beneficial system of the Catholic Church. This is done from four great interrelated objectives. The first one is studying the organization and the composition of the community of beneficiaries of the Vic’s church of Pietat. The second objective is to analyse how the Vic’s society is affected by the tridentin modifications in the Catholic Church’s beneficial system. The third is to know to what extent the dispositions of the council modify the social relationships and, if that is the case, determine if the case is specific to Vic’s bishopric or if it is extrapolatable to other places. The fourth objective is to study the relation between the Economy, the Church and the Society. The thesis is about the community of beneficiaries of the Vic’s church of Pietat between its foundation (1613) and the translocation of the Martyr Saints relics to the major altar of the church of Pietat (1664). The community of beneficiaries of the church of Pietat is created by the beneficiaries of Capbreu of the cathedral. This is done as an instrument in their fight with the Capitol of canons in order to become a college. This study analyses how the community of beneficiaries is founded, who forms part of it and where it is located. The study also analyses the relations with other collectives – such as the episcopal institution, the Capitol of canons, the Capbreu of the cathedral and the Municipal Council. Finally, the study investigates how it is consolidated, how it is organized and what transcendence it has in the city’s economic life and its social role.
Torras, Pastor-Cano Rafael. "La lógica del don : una aproximación histórica, antropológica y económica aplicada a la empresa SEAT." Doctoral thesis, Universitat Abat Oliba, 2017. http://hdl.handle.net/10803/456088.
Повний текст джерелаLos dones, nos explican los historiadores, pueden ser del estilo “te doy para que me des” (clientelismo o intercambio) o del estilo “te doy para que des a otros” (cadena de favores). Los antropólogos nos enseñan cuándo puede hablarse de auténtico don o de generosidad aparente. Los economistas, a partir del concepto de economías externas positivas explican, a través de la difusión del conocimiento y del aprendizaje por experiencia, la presencia de dones en el funcionamiento de los mercados. Debido a que, en los casos citados, el beneficio social es mayor que el rendimiento privado para el promotor. Se presenta como ejemplo un caso real: la introducción del automóvil en España a través de los primeros años de la empresa SEAT. Se concluye con la afirmación de que el don aparece por derecho propio en la ciencia económica.
The gifts, the historians explain to us, can be of the style "I give you in order that you give me" (clientelism or exchange) or of the style "I give you in order that you give to others" (chain of favours). The anthropologists teach us when one can speak about authentic gift or about apparent generosity. The economists, from the concept of external positive economies, explain across the diffusion of knowledge and of learning by doing, the presence of gifts in the functioning of the markets. Due to the fact that, in the mentioned cases, the social benefit is higher than the private one for the promoter. The study presents as an example of a real case: the introduction of the car in Spain across the first years of the company SEAT. The conclusion is that gifts are very much present in the real economy as “animal spirits”.
Moltó, Valiente Consolación. "Beneficio clínico de los fármacos antineoplásicos aprobados por las agencias reguladoras." Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/673750.
Повний текст джерелаLa mejor comprensión de la base molecular del cáncer ha llevado al rápido desarrollo de nuevos fármacos antineoplásicos. Existe la preocupación sobre si estos tratamientos brindan un beneficio limitado. Como respuesta a este reto, las sociedades oncológicas han intentado proporcionar un enfoque estandarizado para evaluar el beneficio clínico de los tratamientos. La US Food and Drug Administration (FDA) ha creado diferentes programas y designaciones para acelerar el desarrollo, revisión y aprobación de medicamentos. En 2012, se estableció la designación Breakthrough Therapy para acelerar el desarrollo y revisión de medicamentos prometedores destinados a tratar enfermedades graves o potencialmente mortales si la evidencia clínica preliminar sugería una mejora sustancial en un criterio de valoración clínicamente significativo sobre los tratamientos disponibles. Sin embargo, los beneficios del sistema actual de revisión y aprobación rápidas son inciertos. Además, los criterios de la FDA permiten que los medicamentos antineoplásicos se aprueben en base a criterios de valoración subrogados o intermedios, a pesar de que su gran mayoría no se han validado como sustitutos de criterios definitivos tales como la supervivencia global (SG) o la calidad de vida. Esto puede limitar la valoración del beneficio clínico de los nuevos tratamientos. El objetivo principal de esta tesis fue evaluar el beneficio clínico de los fármacos antineoplásicos para poder realizar una mejor selección de los tratamientos y ofrecer a los pacientes la opción terapéutica más adecuada. Como objetivos secundarios se propuso: (1) evaluar si aquellos fármacos designados como Breakthrough Therapy ofrecen un mayor beneficio clínico respecto a aquellos que no reciben esta designación, y (2) explorar la asociación entre la SG, la calidad de vida y el beneficio clínico en el momento de la aprobación por la FDA y en el período post-comercialización. Entre los 106 ensayos que respaldaron la aprobación de 52 fármacos antineoplásicos para 96 indicaciones de tumores sólidos, desde julio de 2012 (fecha de creación del programa Breakthrough Therapy) hasta diciembre de 2017, el 43%, 73%, 34% y 69% de los estudios cumplieron con los umbrales de beneficio clínicamente significativo establecidos por la American Society of Clinical Oncology Value Framework (ASCO-VF), el American Society of Clinical Oncology Cancer Research Committee (ASCO-CRC), la European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) y la National Comprehensive Cancer Network (NCCN) Evidence Blocks, respectivamente. Por otro lado, aquellos medicamentos que recibieron la designación Breakthrough Therapies (40% de las indicacions) tuvieron más probabilidades de aportar un beneficio clínico sustancial con la ASCO-VF y los NCCN Evidence Blocks, pero no con la ESMO-MCBS o los criterios del ASCO-CRC. Respecto a la asociación entre la SG, la calidad de vida y el beneficio clínico en el momento de la aprobación por la FDA y en el período posterior a la comercialización, se revisaron un total de 58 fármacos antineoplásicos aprobados por la FDA entre enero de 2006 y diciembre de 2015 para 96 indicaciones de tumores sólidos respaldadas por 96 ensayos. El seguimiento durante el periodo post-comercialización se realizó hasta abril de 2019. La proporción de estudios que demostraron beneficio en la SG pasó del 41% en el momento de la aprobación al 47% con los datos actualizados durante el periodo post-comercialización, mientras que para la calidad de vida, la proporción de estudios que demostraron beneficio fue del 36% en el momento de la aprobación y del 46% con los datos actualizados durante el periodo post-comercialización. Al evaluar el beneficio clínico en el momento de la aprobación, un 27% y 33% de los ensayos mostraron un beneficio clínico sustancial al aplicar las escalas de ESMO-MCBS y la ASCO-VF, respectivamente. Sin embargo, en el periodo post-comercialización, estos porcentajes se incrementaron al 54% aplicando ambas escalas.
Improved understanding of the molecular basis of cancer, has led to rapid development of new drugs. There are some concerns whether advances in cancer therapy provide limited meaningful benefit to patients. To clarify these limitations, oncology societies have attempted to provide a standardized approach to grading clinical benefit. The US Food and Drug Administration (FDA) has created different programs and designations to expedite the development, review and approval of drugs. In 2012, the Breakthrough Therapy Designation was established to expedite the development of FDA approval of such therapies as well as promising new medications intended to treat other serious or life-threatening conditions if preliminary clinical evidence suggests a substantial improvement in a clinically significant endpoint over available treatments. The benefits of the current system of rapid review and approval are uncertain. Furthermore, FDA criteria allow cancer drugs to be approved based on surrogate measures. Most intermediate endpoints have not been validated as surrogates for definitive outcomes such as overall survival (OS) or quality of life, yet are used as primary endpoints in trials supporting drug approval. This can limit the understanding of clinical benefit of new drugs. The main objective of this thesis was to assess the clinical benefit of anticancer drugs in order to make a better choice of treatments and offer patients the most appropriate therapeutic option. As secondary objectives we aimed to: (1) compare the magnitude of clinical benefit of breakthrough-designated and non-breakthrough-designated cancer drug and (2) explore the association between OS, quality of life, and clinical benefit at the time of FDA approval and in the post-marketing period. Among the 106 trials supporting approval of 52 anticancer drugs for 96 solid tumor indications, from July 2012 (date of creation of the Breakthrough Therapy program) to December 2017, 43%, 73%, 34%, and 69% met clinically significant benefit thresholds established by the American Society of Clinical Oncology Value Framework (ASCO-VF), the American Society of Clinical Oncology Cancer Research Committee (ASCO-CRC), the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the National Comprehensive Cancer Network (NCCN) Evidence Blocks scales, respectively. On the other hand, those drugs that received Breakthrough Therapy designation (40% of indications) were more likely than non-breakthrough therapy drugs to be scored as providing a high clinical benefit with the ASCO-VF and the NCCN Evidence Blocks but not with the ESMO-MCBS or the ASCO-CRC scale. Regarding the association between OS, quality of life, and clinical benefit at the time of FDA approval and in the post-marketing period, 58 drugs for 96 indications based on 96 trials were approved by the FDA between January 2006 and December 2015. Post-marketing follow-up was conducted until April 2019. The proportion of trials that showed an improvement in OS increased from 41% at the time of FDA approval to 47 % in the post-marketing period. However, the proportion of trials that showed an improvement in quality of life was 36% at the time of FDA approval and 46% in the post-marketing period. Finally, at the time of approval, 27% and 33% trials met substantial benefit thresholds using ESMO-MCBS and ASCO-VF, respectively whereas in the post-marketing period, 54% trials met the substantial benefit thresholds using both scales.
Universitat Autònoma de Barcelona. Programa de Doctorat en Medicina
FAVERO, GAIA. "OBESITÀ ED EFFETTI BENEFICI DELL'EMEOSSIGENASI." Doctoral thesis, Università degli Studi di Milano, 2012. http://hdl.handle.net/2434/168381.
Повний текст джерелаPosner, Eric. "Coloquio de análisis costo- beneficio: análisis del costo- beneficio como una solución al problema principal- agente." THĒMIS-Revista de Derecho, 2014. http://repositorio.pucp.edu.pe/index/handle/123456789/108100.
Повний текст джерелаEsquivel, Guerra Alejandro. "“ILEGALIDAD DE LAS REGLAS DE CARÁCTER GENERAL FRENTE AL ARTÍCULO 364 DEL CÓDIGO FINANCIERO DEL ESTADO DE MÉXICO Y MUNICIPIOS”." Tesis de Licenciatura, Universidad Autónoma del Estado de México, 2015. http://hdl.handle.net/20.500.11799/67197.
Повний текст джерелаChicu, Doriana. "Employees and customers in call centres: confirmatory and exploratory study." Doctoral thesis, Universitat Rovira i Virgili, 2015. http://hdl.handle.net/10803/396290.
Повний текст джерелаEl presente estudio es una conexión entre las disciplinas de RH y Marketing, y examina el modelo service-profit chain (SPC) en el sector de Call Centre, caracterizado por un servicio remoto y un negocio basado en la reducción de costes. Los datos se han colectado del Proyecto “Global Call Center Project”. Hemos realizado dos estudios. En el primer estudio (confirmatorio) se ha empleado una muestra internacional (n = 937). En el segundo estudio (exploratorio) utilizamos una muestra española (n = 109). Los resultados revelan que el modelo SPC tiene una aplicación diferente en los call centres. Aunque a nivel general podemos confirmar la mayoría de las relaciones del modelo, los resultados indican que la satisfacción del cliente es un resultado separado, y no un precursor de rendimiento de la empresa. También encontramos una alternativa de medir el constructo individual de satisfacción del empleado con los datos organizacionales disponibles. Adicionalmente, descubrimos ciertas discrepancias en la relación entre la productividad y la satisfacción de los empleados.
This thesis is an interface between HR and Marketing discipline, by examining the Service-Profit Chain (SPC) model in the context of call centre, characterized by remote service and cost cutting business models. Data was gathered from the Global Call Centre Project. We carried out two studies. The first one is a confirmatory study, using an international sample (n=937). In the second study we use a Spanish sample (n=109) and carry out an exploratory study. Findings reveal that the SPC model behaves somewhat differently in call centres. Although there is general support for most of the links in the model, the results indicate that customer satisfaction in the call centre industry is a separate outcome, rather than a precursor to company performance. In addition, we found a way to measure the individual level of employee satisfaction construct with organizational available data. We also discovered some discrepancies in the relationship between employee satisfaction and employee productivity.
Sendra, Albiñana Álvaro. "El beneficio de exoneración del pasivo insatisfecho." Doctoral thesis, Universitat Jaume I, 2017. http://hdl.handle.net/10803/403438.
Повний текст джерелаThe recent establishment in our insolvency law of the benefit of exoneration of unsatisfied debt or debt release colloquially known as "second chance" is analyzed in this thesis from a theoretical and systematic point of view along with various systems of comparative law. After analyzing the legal nature, the subjective and objective element of the institution, the thesis reviews the requirements for obtaining it and the various ways of obtaining the benefit, as well as its scope and extent once granted. Proposals are made LEGE FERENDA for a better regulation of such a curative measure of the crisis of the individual.
Mejía, Trujillo Elliot Gianfranco. "El análisis costo-beneficio de las normas." Bachelor's thesis, Universidad Nacional Mayor de San Marcos, 2008. https://hdl.handle.net/20.500.12672/3054.
Повний текст джерелаTesis
Matos, Ortega Margarett. "¿Beneficios o Derechos Penitenciarios?" Derecho & Sociedad, 2017. http://repositorio.pucp.edu.pe/index/handle/123456789/117720.
Повний текст джерелаКниги з теми "De beneficii"
Savu, Constantin. Siguranța alimentelor: Riscuri și beneficii. București: Semne, 2004.
Знайти повний текст джерелаD'Orta, Maurizio. Sterilis beneficii conscientia: Dalla praeceptio al legatum per praeceptionem. Torino: G. Giappichelli, 2005.
Знайти повний текст джерелаSeneca, Lucius Annaeus, approximately 4 B.C.-65 A.D., ed. Le regole del beneficio: Commento tematico a Seneca, De beneficiis, libro I. Palermo: Palumbo, 2013.
Знайти повний текст джерелаBenefattori e beneficati: La relazione asimmetrica nel De beneficiis di Seneca. Palermo: Palumbo, 2009.
Знайти повний текст джерелаBen, Jonson. Beneficia. [s.l.]: [Officina Borogovi], 1998.
Знайти повний текст джерелаJiménez, Juan Torres. Beneficio de inventario. Córdoba: Casa de Galicia, 1993.
Знайти повний текст джерелаDegl'Innocenti, Leonardo. I benefici penitenziari. Milano: Giuffré Editore, 2014.
Знайти повний текст джерела1941-, Hvížďala Karel, and Salivarová Zdena 1933-, eds. Benefice. Toronto, Ont., Canada: Sixty-Eight Publishers, 1990.
Знайти повний текст джерелаSvětlík, Eduard. Benefice --. Praha: Československý spisovatel, 1987.
Знайти повний текст джерелаYourcenar, Marguerite. A beneficio de inventario. Madrid: Ediciones Alfaguara, 1987.
Знайти повний текст джерелаЧастини книг з теми "De beneficii"
Bährle-Rapp, Marina. "beneficial." In Springer Lexikon Kosmetik und Körperpflege, 62. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-71095-0_1068.
Повний текст джерелаSoto Álvarez, Javier. "Análisis coste-beneficio." In Evaluación económica de medicamentos y tecnologías sanitarias:, 85–92. Madrid: Springer Healthcare Iberica, 2012. http://dx.doi.org/10.1007/978-84-940346-6-4_7.
Повний текст джерелаReinhard-DeRoo, Matthias. "Introduction." In Beneficial Ownership, 1–2. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_1.
Повний текст джерелаReinhard-DeRoo, Matthias. "The Term Beneficial Ownership." In Beneficial Ownership, 3–27. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_2.
Повний текст джерелаReinhard-DeRoo, Matthias. "Beneficial Ownership as a Concept." In Beneficial Ownership, 29–38. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_3.
Повний текст джерелаReinhard-DeRoo, Matthias. "Common Law, Equity, and Beneficial Ownership." In Beneficial Ownership, 39–44. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_4.
Повний текст джерелаReinhard-DeRoo, Matthias. "Beneficial Ownership in U.S. Supreme Court Decisions." In Beneficial Ownership, 45–79. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_5.
Повний текст джерелаReinhard-DeRoo, Matthias. "Fundamental Aspects of Federal Indian Law." In Beneficial Ownership, 81–111. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_6.
Повний текст джерелаReinhard-DeRoo, Matthias. "The Beneficial Ownership Concept Applied in Federal Indian Law." In Beneficial Ownership, 113–44. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_7.
Повний текст джерелаReinhard-DeRoo, Matthias. "Epilogue." In Beneficial Ownership, 145–46. Cham: Springer International Publishing, 2013. http://dx.doi.org/10.1007/978-3-319-01686-3_8.
Повний текст джерелаТези доповідей конференцій з теми "De beneficii"
"Properties of Fly Ash-Based Geopolymer Mortars." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720256.
Повний текст джерела"Mechanical Properties of Concrete Made with Fluff." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720253.
Повний текст джерела"Investigation of High Strength Concrete Behavior Made with Very High Percentages of Metakaolin and Steel Fibers." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720252.
Повний текст джерела"Pervious Concrete Production using Recycled Waste Latex Paint." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720264.
Повний текст джерела"Self-Consolidating Concrete using FRAP and High Volume of Supplementary Cementitious Materials." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720257.
Повний текст джерела""CDW Integrated Management, from Linear to Circular Economy in Bogota"." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720266.
Повний текст джерела"Utilization of Reclaimed Asphalt Pavement Aggregates in Portland Cement Concrete for Concrete Pavement." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720251.
Повний текст джерела"Mechanical Performance of Concrete Incorporating Slender Elements from Recycling GFRP Waste." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720250.
Повний текст джерела"Properties and durability of polyvinyl alcohol (PVA) fiber-reinforced rubber mortar." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720258.
Повний текст джерела"Durability of Class C Fly Ash-Based Alkali Activated Concrete." In SP-334: Sustainable Concrete with Beneficial Byproducts. American Concrete Institute, 2019. http://dx.doi.org/10.14359/51720261.
Повний текст джерелаЗвіти організацій з теми "De beneficii"
Barragán Hernández, Wilson Andrés, Christian Thomas Carvajal Bazurto, Sara Isabel Upegui Gómez, and Danilo Portilla Pinzón. Beneficios: Beneficios económicos, sociales y ambientales. Corporación Colombiana de Investigación Agropecuaria - AGROSAVIA, 2022. http://dx.doi.org/10.21930/agrosavia.infografia.2022.2.
Повний текст джерелаArguello, Ricardo, Ricardo Delgado, Mónica Espinosa, Tomás Gonzalez, and Jose Manuel Sandoval. Análisis costo-beneficio de las opciones para alcanzar cero emisiones netas en Colombia. Inter-American Development Bank, October 2022. http://dx.doi.org/10.18235/0004502.
Повний текст джерелаFox, M. R. Beneficial uses of radiation. Office of Scientific and Technical Information (OSTI), October 1991. http://dx.doi.org/10.2172/6084715.
Повний текст джерелаMishkin, Frederic. Is Financial Globalization Beneficial? Cambridge, MA: National Bureau of Economic Research, December 2005. http://dx.doi.org/10.3386/w11891.
Повний текст джерелаAriza Molina, Flor Manuela, Fredys Padilla González, and Alexander Salazar Montoya. Evaluación económica de la rentabilidad de cafés especiales de la variedad Tabí en el municipio de Manaure - Cesar. Universidad Nacional Abierta y a Distancia, April 2022. http://dx.doi.org/10.22490/ecacen.4264.
Повний текст джерелаBunch, J. R. Acceptance for beneficial use document. Office of Scientific and Technical Information (OSTI), January 1997. http://dx.doi.org/10.2172/328698.
Повний текст джерелаRussell-Prywata, Louise. Beneficial ownership and wealth taxation. CAGE, December 2020. http://dx.doi.org/10.47445/124.
Повний текст джерелаCrowley, David E., Dror Minz, and Yitzhak Hadar. Shaping Plant Beneficial Rhizosphere Communities. United States Department of Agriculture, July 2013. http://dx.doi.org/10.32747/2013.7594387.bard.
Повний текст джерелаTerry Brown, Carol Frost, Thomas Hayes, Leo Heath, Drew Johnson, David Lopez, Demian Saffer, Michael Urynowicz, John Wheaton, and Mark Zoback. Produced Water Management and Beneficial Use. Office of Scientific and Technical Information (OSTI), October 2007. http://dx.doi.org/10.2172/947090.
Повний текст джерелаCrowley, David, Yitzhak Hadar, and Yona Chen. Rhizosphere Ecology of Plant-Beneficial Microorganisms. United States Department of Agriculture, February 2000. http://dx.doi.org/10.32747/2000.7695843.bard.
Повний текст джерела